AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin

AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.

Elevate Your Investing Strategy:

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ABBV:

Disclaimer & DisclosureReport an Issue

AbbVie price target raised to $250 from $236 at Raymond James 3 Best Dividend Aristocrat Stocks to Buy Now, 10/16/2025 AbbVie’s Phase 2 Study on CLL/SLL Treatment: Key Updates and Market Impact AbbVie’s Venetoclax Study Completion: A Potential Boost for Investors Psychedelic: Needham initiates coverage of atai, GH Research, MindMed

View Comments